IMBDX to Present Breakthrough CancerFind Research at ESMO 2024 Congress

Precision medicine company IMBDX has announced plans to present groundbreaking research results utilizing its innovative multi-cancer screening service, ‘CancerFind’, at the 2024 European Society for Medical Oncology (ESMO) Congress in Spain.

CancerFind is a pioneering product developed by IMBDX that can detect multiple cancers (currently 8 types of cancer) at an early stage with a simple blood test. This technology has the potential to significantly reduce the economic burden of cancer treatment and increase patient survival rates.

At ESMO 2024, IMBDX will reveal CancerFind’s performance on eight major cancers, including colorectal, stomach, liver, pancreatic, lung, breast, ovarian, and prostate. The technology is characterized by its use of an artificial intelligence (AI) algorithm that significantly improves the analysis efficiency of cancer genome data, laying the foundation for screening a wider range of cancer types.

Notably, CancerFind has achieved sensitivities of 80.6% and 84.7% for pancreatic cancer and ovarian cancer, respectively, for which there is currently no standard screening test. This breakthrough has the potential to present new possibilities for the treatment of cancers that have been difficult to detect early and have had poor prognoses.

According to Kim Tae-yoo, CEO of IMBDX, “Early detection of cancer is a crucial factor in increasing the survival rate of cancer patients.” He added, “Our goal is to strengthen our product competitiveness to enable early detection of more than 26 types of cancer with a single blood test, securing the golden time for incurable cancer treatment and contributing to the promotion of national health.”